API | darapladib

darapladib Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Darapladib is an inhibitor lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis. ^Wikipedia

Chemistry

SMILES: CCN(CC)CCN(Cc1ccc(cc1)c2ccc(cc2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCc5ccc(F)cc5
InChIKey: WDPFJWLDPVQCAJ-UHFFFAOYSA-N
Mol. Mass: 666.79
ALogP: 7.22 Partition coefficient
ChEMBL Molecule:
darapladib

More Chemistry

Pharmacology

Mechanism of Action:
- Platelet-activating factor acetylhydrolase (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

darapladib | sb480848 | sb 480848 | sb-480848

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Atherosclerosis

Experimental Indications - Clinical Trial Phases 1-4 (4)

Acute Coronary Syndrome (Phase 3)

Atherosclerosis (Phase 3)

Diabetic Retinopathy (Phase 2)

Endothelial Cells (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 21
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue